Netupitant; Palonosetron Hydrochloride Patent Expiration
Netupitant; Palonosetron Hydrochloride is Used for preventing chemotherapy-induced nausea and vomiting in adults. It was first introduced by Helsinn Healthcare Sa
Netupitant; Palonosetron Hydrochloride Patents
Given below is the list of patents protecting Netupitant; Palonosetron Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Akynzeo | US10233154 | Crystalline forms of an NK-1 antagonist | Sep 25, 2035 | Helsinn Hlthcare |
| Akynzeo | US10676440 | Crystalline forms of an NK-1 antagonist | Sep 25, 2035 | Helsinn Hlthcare |
| Akynzeo | US10828297 | Compositions and methods for treating centrally mediated nausea and vomiting | Dec 17, 2030 | Helsinn Hlthcare |
| Akynzeo | US10961195 | Crystalline forms of an NK-1 antagonist | Sep 25, 2035 | Helsinn Hlthcare |
| Akynzeo | US11559523 | Compositions and methods for treating centrally mediated nausea and vomiting | Nov 18, 2030 | Helsinn Hlthcare |
| Akynzeo | US5202333 | Tricyclic 5-HT3 receptor antagonists |
Apr 13, 2015
(Expired) | Helsinn Hlthcare |
| Akynzeo | US6297375 | 4-phenyl-pyridine derivatives |
Mar 17, 2023
(Expired) | Helsinn Hlthcare |
| Akynzeo | US8623826 | Compositions and methods for treating centrally mediated nausea and vomiting | Nov 18, 2030 | Helsinn Hlthcare |
| Akynzeo | US8951969 | Compositions and methods for treating centrally mediated nausea and vomiting | Nov 18, 2030 | Helsinn Hlthcare |
| Akynzeo | US9186357 | Compositions and methods for treating centrally mediated nausea and vomiting | Nov 18, 2030 | Helsinn Hlthcare |
| Akynzeo | US9271975 | Compositions and methods for treating centrally mediated nausea and vomiting | Sep 09, 2031 | Helsinn Hlthcare |
| Akynzeo | US9943515 | Compositions and methods for treating centrally mediated nausea and vomiting | Nov 18, 2030 | Helsinn Hlthcare |
| Akynzeo | US9951016 | Crystalline forms of an NK-1 antagonist | Sep 25, 2035 | Helsinn Hlthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳